In addition, the percentage of cells positive for proliferation marker Ki67 was decreased by 3.4-fold in Sphk2-KO livers (Fig. 2H), suggesting that SphK2 deficiency might exhibit anti-NAFLD-HCC effects at the cellular level. Here, SPHK2 is linked to metabolic dysfunction-associated steatotic liver disease.